Why the study?
Do metabolically stable apelin-17 analogues improve plasma half-life and lower blood pressure compared to native apelin-17 isoforms?
Do metabolically stable apelin-17 analogues improve plasma half-life and lower blood pressure compared to native apelin-17 isoforms?
Metabolically stable apelin-17 analogues demonstrate significantly prolonged plasma half-life and pronounced blood pressure-lowering effects, highlighting their potential for preventing ischemia-reperfusion injury.
Preclinical BP-lowering data warrant no practice change; leaves open translation of stable apelin analogues to human trials.
assay show moderate blood pressure-lowering effects. The corresponding apelin-17 analogues show pronounced blood pressure-lowering effects and up to a 340-fold increase in plasma half-life compared to the native apelin-17 isoforms, suggesting their potential use in the design of metabolically stable apelin analogues to prevent IR injury.
No takes yet. Share an insight, caveat, or question.
Fernandez et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: